A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
G
Greg Durm, MD
Primary Investigator
Overview
To determine the recommended Phase 2 dose (RP2D) of LY3537982 monotherapy in patients with KRAS G12C-mutant advanced solid tumors
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
cancer,KRAS G12C-Mutant Advanced Solid Tumors
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 12289
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
